

EBC Markets Briefing | German stocks extend losing streak

The DAX 40 fell for a fourth straight session on Tuesday, dragged down by heavyweight financial and healthcare stocks. The EU has done well in striking preliminary deals with new partners in pursuit of trade diversification.

The 30% tariff on European goods would, if implemented, be a game-changer for Europe, wiping out transatlantic commerce and forcing a rethink of its export-led economic model. Barclays estimate the proposed rate on EU goods including both reciprocal and sectoral duties combined with a 10% retaliation from Brussels would eat up most of the bloc's already meagre growth. Analysts have been steadily revising down 2025 earnings forecasts for 55 consecutive weeks. Full-year earnings growth for Europe is now expected at 3%, down from 8% at the start of the year. EPS downgrades often mean that stocks can perform well through reporting season as the bar to beat expectations is lower. Deutsche Bank noted lighter positioning in equities this time around could amplify that effect. The euro's strength is another emerging issue. This poses a problem for the market's export-focused constituents, which derive just 40% of revenue from within Europe.

The DAX index remains supported by 50 SMA, and the double-bottom pattern indicates continued rally beyond 24,100. But the uptrend is vulnerable to headlines in the longer term. EBC Forex Market Analysis Disclaimer: This material is for general information purposes only and is not intended as (and should not be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by EBC Industry In-depth Analysis or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

Learn more

Contact:

mkt@ebc.com

Disclaimer:

Investment involves risk. The content of this report is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product.

Publication date:

2025-07-16 16:16:09 (GMT)

The terms and conditions of use set out below (referred to as "FX Blue's Terms"), form a contractual agreement governing FX Blue's relationship with you in relation to your use of this Website (“Agreement”) and you agree to be legally bound by FX Blue's Terms just as if you had signed this Agreement. By using this Website and any Information, you are agreeing to comply with and be bound by FX Blue's Terms, including any revisions that may be made to FX Blue's Terms from time to time. FX Blue reserves the right, in FX Blue's sole discretion, to change, modify, add or remove portions of FX Blue's Terms at any time by posting the revisions on the Website. You should check FX Blue's Terms periodically for changes as by using the Website after FX Blue posts any changes to FX Blue's Terms, you are agreeing to accept those changes, whether or not you have reviewed them, and you waive any right you may have to receive individualised notice of such changes. FX Blue's Terms may be supplemented by additional terms and conditions pertaining to specific content and activities. You agree and understand that such additional terms and conditions are hereby incorporated by reference to FX Blue's Terms. Your continued use of the Website means that you accept any new or modified FX Blue Terms.

​EBC Markets Briefing | German stocks extend losing streak

EBC Markets Briefing | German stocks extend losing streak